The Appl-1, Sortilin, and Syndecan-1 biomarker panel addresses critical diagnostic challenges in prostate cancer pathology by enhancing the accuracy of detection and reproducibility of Gleason grading and ISUP group assignment. This evidence concerns the gene SDC1 and Familial prostate cancer.